Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

In silico structural biology studies inform the identification of “druggable” pockets in previously understudied dependencies with tumor type/lineage-selective roles.

Evangelos Papadopoulos, Ricardo De Matos Simoes, Olga Dashevsky, Huihui Tang, Eleni Anastasakou, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Yuefang Deng, Aktas Bertal, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 2581.

https://doi.org/10.1182/blood-2025-2581

Published: 2025

Journal Articles

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

Shannon Matulis, Jonathan Patton, Rebecca Owens, Robert Chavez, Arun Wiita, Mala Shanmugam, Constantine Mitsiades, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise

Blood (2025) 146 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2025-2177

Published: 2025

Journal Articles

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Huihui Tang, Ricardo De Matos Simoes, Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Eleni Anastasakou, Oliver Bohorquez, Shizuka Yamano, Evangelos Papadopoulos, Lisa Leypoldt, Arun Wiita, Olwyn Mahon, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 2173.

https://doi.org/10.1182/blood-2025-2173

Published: 2025

Journal Articles

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Olga Dashevsky, Ricardo De Matos Simoes, Huihui Tang, Torsten Steinbrunn, Shizuka Yamano, Eleni Anastasakou, Benjamin Barwick, Sara Gandolfi, Ryosuke Shirasaki, Vikas Gupta, Michal Sheffer, Jonathan Licht, Lawrence Boise, Matthew Oser, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 688.

https://doi.org/10.1182/blood-2025-688

Published: 2025

Journal Articles

Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes

Yusuke Yamashita, Jonathan Patton, Yuliza Shotts, Megan Du, Meaghen Sharik, Kirsten Pfeffer, Yuan Zhu, Chang-Xin Shi, Caleb Stein, Erin Meermeier, Marta Chesi, Lanbo Xiao, Arul Chinnaiyan, Benjamin Barwick, P. Leif Bergsagel

Blood (2025) 146 (Supplement 1): 2138.

https://doi.org/10.1182/blood-2025-2138

Published: 2025

Journal Articles

NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma

Anna Baj, Jonathan Patton, Robert Chavez, Shannon Matulis, Doris Powell, Mala Shanmugam, Arun Wiita, Constantine Mitsiades, Jonathan Keats, Jonathan Licht, Sagar Lonial, Lawrence Boise, Benjamin Barwick

Blood (2025) 146 (Supplement 1): 572.

https://doi.org/10.1182/blood-2025-572

Published: 2025

Journal Articles

Impact of extrinsic heme on adoptive T cell therapy

Dejah Blake, Pulkit Gupta, Remya Nair, Ruby Freeman, Heather Lin, Sagar Lonial, Benjamin Barwick, Ajay Nooka, Jean Koff, Sarwish Rafiq, Mala Shanmugam

Blood (2025) 146 (Supplement 1): 7628.

https://doi.org/10.1182/blood-2025-7628

Published: 2025

Journal Articles

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Kiran Lakhani, Yu Zhang, Jonathan Keats, Vikas Gupta, Sagar Lonial, Nisha Joseph, Ajay Nooka, Benjamin Barwick, Lawrence Boise

Blood (2025) 146 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2025-2251

Published: 2025

Journal Articles

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Torsten Steinbrunn, Arnold Bolomsky, Ryosuke Shirasaki, Omar Al-Odat, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Oliver Bohorquez, Brian Glassner, Eleni Anastasakou, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Ricardo De Matos Simoes, James Christensen, Ryan Young, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 327.

https://doi.org/10.1182/blood-2025-327

Published: 2025

Journal Articles

NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma

Robert Chavez, Jonathan Patton, James Ackley, Mala Shanmugam, Constantine Mitsiades, Arun Wiita, Jonathan Licht, Erin Flynt, Terry Connolly, Karen Conneely, Sagar Lonial, Lawrence Boise, Benjamin Barwick

Blood (2025) 146 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2025-3956

Published: 2025

Journal Articles

Functional genomic screens identify positive and negative regulators of venetoclax resistance

Beena Thomas, Karanpreet Bhatia, Devin Bog, Benjamin Barwick, Constantine Mitsiades, Lawrence Boise, Vikas Gupta

Blood (2025) 146 (Supplement 1): 5733.

https://doi.org/10.1182/blood-2025-5733

Published: 2025

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma

Vikas A. Gupta, MD PhD, Benjamin Barwick, PhD, Scott Newman, PhD, Jonathan J. Keats, PhD, Daniel Auclair, PhD, Shannon Matulis, PhD, Michael R. Rossi, PhD, Ajay K. Nooka, MDMPH, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Lawrence H. Boise, PhD

Blood (2017) 130 (Supplement 1): 3073.

https://doi.org/10.1182/blood.V130.Suppl_1.3073.3073

Published: 2017

Journal Articles

High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations

Benjamin Barwick, PhD, Vikas A. Gupta, MD PhD, Daniel Auclair, PhD, Jonathan J. Keats, PhD, Sagar Lonial, MD, Paula M Vertino, PhD, Lawrence H. Boise, PhD

Blood (2017) 130 (Supplement 1): 1780.

https://doi.org/10.1182/blood.V130.Suppl_1.1780.1780

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

In silico structural biology studies inform the identification of “druggable” pockets in previously understudied dependencies with tumor type/lineage-selective roles.

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes

NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma

Impact of extrinsic heme on adoptive T cell therapy

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma

Functional genomic screens identify positive and negative regulators of venetoclax resistance

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma

High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only